Ratings for Edwards Lifesciences EW were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 5 | 10 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 4 | 9 | 0 | 0 |
| 3M Ago | 1 | 0 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $83.32, a high estimate of $110.00, and a low estimate of $70.00. This current average represents a 15.39% decrease from the previous average price target of $98.47.
Diving into Analyst Ratings: An In-Depth Exploration
A clear picture of Edwards Lifesciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Larry Biegelsen | Wells Fargo | Lowers | Overweight | $80.00 | $90.00 |
| Matt Miksic | Barclays | Lowers | Overweight | $90.00 | $101.00 |
| David Roman | Goldman Sachs | Lowers | Buy | $91.00 | $107.00 |
| Joshua Jennings | TD Cowen | Lowers | Hold | $70.00 | $100.00 |
| Larry Biegelsen | Wells Fargo | Lowers | Overweight | $90.00 | $99.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $76.00 | $91.00 |
| Pito Chickering | Deutsche Bank | Lowers | Buy | $85.00 | $103.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $85.00 | $101.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $82.00 | $110.00 |
| Rick Wise | Stifel | Lowers | Hold | $70.00 | $85.00 |
| Suraj Kalia | Oppenheimer | Lowers | Outperform | $90.00 | $100.00 |
| William Plovanic | Canaccord Genuity | Lowers | Hold | $77.00 | $85.00 |
| Adam Maeder | Piper Sandler | Lowers | Neutral | $73.00 | $88.00 |
| Travis Steed | B of A Securities | Lowers | Neutral | $75.00 | $105.00 |
| Robbie Marcus | JP Morgan | Lowers | Neutral | $72.00 | $105.00 |
| David Rescott | Baird | Lowers | Neutral | $70.00 | $102.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $110.00 | $105.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $106.00 | $105.00 |
| Vijay Kumar | Evercore ISI Group | Raises | In-Line | $91.00 | $89.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Edwards Lifesciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Edwards Lifesciences compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Edwards Lifesciences's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Edwards Lifesciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Edwards Lifesciences analyst ratings.
About Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Edwards Lifesciences: A Financial Overview
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Edwards Lifesciences showcased positive performance, achieving a revenue growth rate of 6.98% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 26.43%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Edwards Lifesciences's ROE stands out, surpassing industry averages. With an impressive ROE of 5.03%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Edwards Lifesciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.69%, the company showcases efficient use of assets and strong financial health.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Understanding the Relevance of Analyst Ratings
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
